Is accelerated, high-dose theta burst stimulation a panacea for treatment-resistant depression?
Kevin A CaulfieldPublished in: Journal of neurophysiology (2019)
A recent study by Williams et al. (Williams NR, Sudheimer KD, Bentzley BS, Pannu J, Stimpson KH, Duvio D, Cherian K, Hawkins J, Scherrer KH, Vyssoki B, DeSouza D, Raj KS, Keller J, Schatzberg AF. Brain 141: e18, 2018) used accelerated, high-dose intermittent theta burst stimulation (iTBS) to treat highly treatment-resistant depression patients. Remarkably, most patients remitted, but the durability of therapeutic response was weak and all patients relapsed within 2 wk posttreatment. This mini-review examines the "fast on, fast off" effects of accelerated, high-dose iTBS for depression and suggests a new treatment that would combine the strengths of multiple extant iTBS protocols.
Keyphrases
- high dose
- end stage renal disease
- chronic kidney disease
- newly diagnosed
- ejection fraction
- low dose
- prognostic factors
- peritoneal dialysis
- depressive symptoms
- stem cell transplantation
- patient reported outcomes
- acute myeloid leukemia
- atrial fibrillation
- diffuse large b cell lymphoma
- sleep quality
- functional connectivity
- resting state
- high intensity
- patient reported